Mazilescu Laura Ioana, Selzner Markus, Selzner Nazia
Ajmera Transplant Program, Toronto General Hospital, Ontario, Canada.
Division of Nephrology, The Hospital for Sick Children, Toronto, Ontario, Canada.
JHEP Rep. 2021 Mar 13;3(3):100265. doi: 10.1016/j.jhepr.2021.100265. eCollection 2021 Jun.
Liver steatosis is emerging as a major cause of chronic liver disease worldwide, mainly due to the increasing rate of obesity, type 2 diabetes, and metabolic syndrome. Because of the increased incidence of liver steatosis, many organs are currently declined for transplantation despite high demand and waiting list mortality. Defatting strategies have recently emerged as a means of rapidly reducing liver steatosis to expand the pool of available organs. This review summarises advances in defatting strategies in experimental and human models of liver steatosis over the last 20 years.
肝脂肪变性正成为全球慢性肝病的主要病因,主要归因于肥胖、2型糖尿病和代谢综合征发病率的上升。由于肝脂肪变性发病率增加,尽管需求高且等待名单上有死亡情况,但目前许多器官被拒绝用于移植。脱脂策略最近已成为一种迅速降低肝脂肪变性以扩大可用器官库的方法。本综述总结了过去20年在肝脂肪变性实验模型和人类模型中脱脂策略的进展。